{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T20:52:27Z","timestamp":1787691147812,"version":"build-2784847793"},"reference-count":25,"publisher":"BMJ","issue":"12","license":[{"start":{"date-parts":[[2020,12,16]],"date-time":"2020-12-16T00:00:00Z","timestamp":1608076800000},"content-version":"unspecified","delay-in-days":15,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2020,11,19]]},"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Dexamethasone (DEX) is administered for multiple days to prevent chemotherapy-induced nausea and vomiting for patients receiving highly emetogenic chemotherapy (HEC); however, its notorious side effects have been widely reported. Although our multicentre randomised double-blind comparative study verified non-inferiority of sparing DEX after day 2 of chemotherapy when combined with neurokinin-1 receptor antagonist (NK1-RA) and palonosetron (Palo) for patients receiving HEC regimen, DEX sparing was not non-inferior in patients receiving cisplatin (CDDP)-based HEC regimens in subgroup analysis. Recently, the efficacy of the addition of olanzapine (OLZ) to standard triple antiemetic therapy on HEC has been demonstrated by several phase III trials. This study aims to confirm non-inferiority of DEX sparing when it is combined with NK-1RA, Palo and OLZ in patients receiving CDDP-based HEC regimens.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and analysis<\/jats:title>\n                    <jats:p>\n                      This is a randomised, double-blind, phase III trial. Patients who are scheduled to receive CDDP \u226550\u2009mg\/m\n                      <jats:sup>2<\/jats:sup>\n                      as initial chemotherapy are eligible. Patients are randomly assigned to receive either DEX on days 1\u20134 or DEX on day 1 combined with NK1-RA, Palo and OLZ (5\u2009mg). The primary endpoint is complete response (CR) rate, defined as no emesis and no rescue medications during the delayed phase (24\u2013120\u2009hours post-CDDP administration). The non-inferiority margin is set at \u221215.0%. We assume that CR rates would be 75% in both arms. Two hundred and sixty-two patients are required for at least 80% power to confirm non-inferiority at a one-sided significance level of 2.5%. After considering the possibility of attrition, we set our final required sample size of 280.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Ethics and dissemination<\/jats:title>\n                    <jats:p>The institutional review board approved the study protocol at each of the participating centres. The trial result will be presented at international conferences and published in peer-reviewed journals.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration number<\/jats:title>\n                    <jats:p>UMIN000032269.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjopen-2020-041737","type":"journal-article","created":{"date-parts":[[2023,3,15]],"date-time":"2023-03-15T02:21:30Z","timestamp":1678846890000},"page":"e041737","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":4,"title":["Study protocol for SPARED trial: randomised non-inferiority phase III trial comparing dexamethasone on day 1 with dexamethasone on days 1\u20134, combined with neurokinin-1 receptor antagonist, palonosetron and olanzapine (5 mg) in patients receiving cisplatin-based chemotherapy"],"prefix":"10.1136","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5836-8305","authenticated-orcid":false,"given":"Hiroko","family":"Minatogawa","sequence":"first","affiliation":[{"name":"Department of Pharmacy, St.Marianna University School of Medicine Hospital, Kawasaki, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoki","family":"Izawa","sequence":"additional","affiliation":[{"name":"Department of Clinical Oncology, St. Marianna University School of Medicine, Kawasaki, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Kawaguchi","sequence":"additional","affiliation":[{"name":"Department of Practical Pharmacy, Tokyo University of Pharmacy and Life Sciences, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tempei","family":"Miyaji","sequence":"additional","affiliation":[{"name":"Department of Clinical Trial Data Management, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuhiro","family":"Shimomura","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Aichi Cancer Center Hospital, Nagoya, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Honda","family":"Kazunori","sequence":"additional","affiliation":[{"name":"Department of Clinical Oncology, Aichi Cancer Center Hospital, Nagoya, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirotoshi","family":"Iihara","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Gifu University Hospital, Gifu, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasushi","family":"Ohno","sequence":"additional","affiliation":[{"name":"Department of Respirology, Gifu University Graduate School of Medicine, Gifu, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yusuke","family":"Inada","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Yokohama Rosai Hospital, Yokohama, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hitoshi","family":"Arioka","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Yokohama Rosai Hospital, Yokohama, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hajime","family":"Morita","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, St. Marianna University Yokohama City Seibu Hospital, Yokohama, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoya","family":"Hida","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, St.Marianna University School of Medicine, Kawasaki, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitsuhiro","family":"Sugawara","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Kitasato University Hospital, Sagamihara, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chikatoshi","family":"Katada","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Kitasato University School of Medicine, Sagamihara, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuichi","family":"Nawata","sequence":"additional","affiliation":[{"name":"Department of Hospital Pharmaceutics, Showa University Northern Yokohama Hospital, Yokohama, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroo","family":"Ishida","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Showa University Northern Yokohama Hospital, Yokohama, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayako","family":"Tsuboya","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, St. Marianna University Kawasakishi Municipal Tama Hospital, Kawasaki, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Tsuda","sequence":"additional","affiliation":[{"name":"Department of Clinical Oncology, St. Marianna University School of Medicine, Kawasaki, Japan"},{"name":"Department of Hepato-Biliary-Pancreatic Center, Shonan Fujisawa Tokushukai Hospital, Fujisawa, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takuhiro","family":"Yamaguchi","sequence":"additional","affiliation":[{"name":"Division of Biostatistics, Tohoku University School of Medicine, Sendai, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takako Eguchi","family":"Nakajima","sequence":"additional","affiliation":[{"name":"Department of Clinical Oncology, St. Marianna University School of Medicine, Kawasaki, Japan"},{"name":"Division of Kyoto Innovation Center for Next Generation Clinical Trials and iPS Cell Therapy, Kyoto University Hospital, Kyoto, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2020,12,17]]},"reference":[{"key":"2025121219521268000_10.12.e041737.1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1515442"},{"key":"2025121219521268000_10.12.e041737.2","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1200\/JCO.1997.15.1.103","article-title":"Proposal for classifying the acute emetogenicity of cancer chemotherapy","volume":"15","author":"Hesketh","year":"1997","journal-title":"J Clin Oncol"},{"key":"2025121219521268000_10.12.e041737.3","article-title":"Optimizing antiemetic treatment for chemotherapy-induced nausea and vomiting in Japan: Update summary of the 2015 Japan Society of Clinical Oncology Clinical Practice Guidelines for Antiemesis","author":"Aogi","year":"2020","journal-title":"Int J Clin Oncol"},{"key":"2025121219521268000_10.12.e041737.4","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1056\/NEJMoa1515725","article-title":"Olanzapine for the prevention of chemotherapy-induced nausea and vomiting","volume":"375","author":"Navari","year":"2016","journal-title":"N Engl J Med"},{"key":"2025121219521268000_10.12.e041737.5","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2003.01.095"},{"key":"2025121219521268000_10.12.e041737.6","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.21222"},{"key":"2025121219521268000_10.12.e041737.7","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdl347"},{"key":"2025121219521268000_10.12.e041737.8","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6603048"},{"key":"2025121219521268000_10.12.e041737.9","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.4143\/crt.2015.464","article-title":"A pilot study evaluating steroid-induced diabetes after antiemetic dexamethasone therapy in chemotherapy-treated cancer patients","volume":"48","author":"Jeong","year":"2016","journal-title":"Cancer Res Treat"},{"key":"2025121219521268000_10.12.e041737.10","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2016-0308"},{"key":"2025121219521268000_10.12.e041737.11","doi-asserted-by":"crossref","DOI":"10.1186\/s12885-019-6454-y","article-title":"Impact of dexamethasone-sparing regimens on delayed nausea caused by moderately or highly emetogenic chemotherapy: a meta-analysis of randomised evidence","volume":"19","author":"Celio","year":"2019","journal-title":"BMC Cancer"},{"key":"2025121219521268000_10.12.e041737.12","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1200\/JCO.2017.74.4375","article-title":"Placebo-controlled, double-blinded phase III study comparing dexamethasone on day 1 with dexamethasone on days 1 to 3 with combined neurokinin-1 receptor antagonist and palonosetron in high-emetogenic chemotherapy","volume":"36","author":"Ito","year":"2018","journal-title":"J Clin Oncol"},{"key":"2025121219521268000_10.12.e041737.13","doi-asserted-by":"crossref","first-page":"2741","DOI":"10.1200\/JCO.2018.78.8109","article-title":"Is the dexamethasone-sparing strategy ready for cisplatin? too early for an answer","volume":"36","author":"Celio","year":"2018","journal-title":"J Clin Oncol"},{"key":"2025121219521268000_10.12.e041737.14","unstructured":"MASCC\/ESMO antiemetic guideline 2016 with updates in 2019, 2019. Available: https:\/\/www.mascc.org\/assets\/Guidelines-Tools\/mascc_antiemetic_guidelines_english_v.1.5SEPT29.2019.pdf"},{"key":"2025121219521268000_10.12.e041737.15","unstructured":"NCCN clinical practice guidelines in oncology: antiemesis Version2. 2020. Available: https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/antiemesis.pdf"},{"key":"2025121219521268000_10.12.e041737.16","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1200\/JOP.2017.026351","article-title":"Antiemetics: American Society of clinical oncology clinical practice guideline update summary","volume":"13","author":"Hesketh","year":"2017","journal-title":"J Oncol Pract"},{"key":"2025121219521268000_10.12.e041737.17","doi-asserted-by":"publisher","DOI":"10.1016\/0893-133X(94)00129-N"},{"key":"2025121219521268000_10.12.e041737.18","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/S1470-2045(19)30678-3","article-title":"Olanzapine 5 Mg plus standard antiemetic therapy for the prevention of chemotherapy-induced nausea and vomiting (J-FORCE): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial","volume":"21","author":"Hashimoto","year":"2020","journal-title":"Lancet Oncol"},{"key":"2025121219521268000_10.12.e041737.19","doi-asserted-by":"publisher","DOI":"10.2337\/diabetes.54.6.1846"},{"key":"2025121219521268000_10.12.e041737.20","doi-asserted-by":"publisher","DOI":"10.1016\/j.suponc.2011.05.002"},{"key":"2025121219521268000_10.12.e041737.21","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/s41687-017-0012-7","article-title":"Japanese translation and linguistic validation of the US National cancer Institute's patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE)","volume":"1","author":"Miyaji","year":"2017","journal-title":"J Patient Rep Outcomes"},{"key":"2025121219521268000_10.12.e041737.22","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/s41687-017-0022-5","article-title":"The Japanese version of the National cancer Institute's patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE): psychometric validation and discordance between clinician and patient assessments of adverse events","volume":"2","author":"Kawaguchi","year":"2017","journal-title":"J Patient Rep Outcomes"},{"key":"2025121219521268000_10.12.e041737.23","doi-asserted-by":"publisher","DOI":"10.1016\/S0959-8049(97)00395-X"},{"key":"2025121219521268000_10.12.e041737.24","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1007\/s10147-017-1200-4","article-title":"A double-blind randomized phase II dose-finding study of olanzapine 10\u00a0mg or 5\u00a0mg for the prophylaxis of emesis induced by highly emetogenic cisplatin-based chemotherapy","volume":"23","author":"Yanai","year":"2018","journal-title":"Int J Clin Oncol"},{"key":"2025121219521268000_10.12.e041737.25","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1093\/jjco\/hyx084","article-title":"A phase II study of palonosetron, aprepitant, dexamethasone and olanzapine for the prevention of cisplatin-based chemotherapy-induced nausea and vomiting in patients with thoracic malignancy","volume":"47","author":"Nakashima","year":"2017","journal-title":"Jpn J Clin Oncol"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2020-041737","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,13]],"date-time":"2025-12-13T03:52:19Z","timestamp":1765597939000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2020-041737"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12]]},"references-count":25,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2020,12,17]]},"published-print":{"date-parts":[[2020,12]]}},"alternative-id":["10.1136\/bmjopen-2020-041737"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2020-041737","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"value":"2044-6055","type":"print"},{"value":"2044-6055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,12]]}}}